AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02243124
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
Trial: NCT02016742
Drug: RDC5
RxNorm normalized name: Relugolix
DrugBank: Relugolix (DB11853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01723501
Drug: 0.25% chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.44% chlorhexidine di-gluconate body wipes which would release 0.25% free chlorhexidine on application
Trial: NCT01723501
Drug: sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water wipes (placebo)
Trial: NCT00003753
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003753
Drug: floxuridine
RxNorm normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003753
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01505491
Drug: adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40mg adalimumab single s.c. injection
Trial: NCT03855306
Drug: Daonil
RxNorm normalized name: Daonil
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 5 mg Glibenclamide
Trial: NCT04117919
Drug: Triamcinolone (Encort-A) 0.1%15g/Tube
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: only Topical steroids
Trial: NCT00153634
Drug: IV ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/kg every 8 hours, up to 2 grams every 8 hours
Trial: NCT00153634
Drug: PO ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg every 12 hours if weight \<50 kg 750 mg every 12 hours if weight ≥50 kg
Trial: NCT00153634
Drug: IV meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/kg every 8 hours, up to 2 grams every 8 hours
Trial: NCT00153634
Drug: IV piperacillin-tazobactam
RxNorm normalized name: piperacillin / tazobactam
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/kg of piperacillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
Trial: NCT00153634
Drug: IV ticarcillin-clavulanate
DrugBank: Ticarcillin (DB01607)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/kg of ticarcillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
Trial: NCT03988816
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500Mcg Tab, once daily
Trial: NCT01327339
Drug: Ropinirole
RxNorm normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Basically there is no treatment allocation. Subjects who would be administered of ropinirole at their physician's direction will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Trial: NCT00199186
Drug: imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00199186
Drug: vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00199186
Drug: cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00199186
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00199186
Drug: idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00199186
Drug: dexamethasone (intrathecal)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00309777
Drug: Pitavastatin
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin once daily
Trial: NCT01016483
Drug: Pimasertib
RxNorm normalized name: Pimasertib
DrugBank: Pimasertib (DB14904)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01016483
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02070705
Drug: Ferumoxytol
RxNorm normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT02481518
Drug: Magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre loading fluid with Magnesium sulphate 16 milliequivalent plus potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
Trial: NCT00514449
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic
Trial: NCT02996695
Drug: Artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate is a succinic ester of artemether.
Trial: NCT02853331
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT02853331
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral capsule
Trial: NCT03925428
Drug: Entinostat
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03925428
Drug: Molibresib
RxNorm normalized name: Molibresib
DrugBank: Molibresib (DB16239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01334112
Drug: Axitinib (AG-013736)
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse
Trial: NCT01424566
Drug: Nabiximols
RxNorm normalized name: Nabiximols
DrugBank: Nabiximols (DB14011)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02996695
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-aminoquinolone, antimalarial agent for oral administration
Trial: NCT01747330
Drug: Pancreatin
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses of Pancreatin \<2500 lipase u/kg/feed or \<4000 lipase U/g fat/intake or \<10000 lipase U/kg/day given orally are used
Trial: NCT03962998
Drug: Lactulose/Rhamnose solution
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose/Rhamnose solution administered orally followed by measurement of excreted lactulose and rhamnose in urine
Trial: NCT03962998
Drug: MB-102
RxNorm normalized name: MB-102 CD123 CAR
DrugBank: MB-102 CD123 CAR (DB17366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MB-102 solution administered orally followed by measurement of excreted MB-102 in urine
Trial: NCT01288378
Drug: caspofungin acetate
RxNorm normalized name: Caspofungin Acetate
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.
Trial: NCT00739297
Drug: Comparator: montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
Trial: NCT01019408
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
Trial: NCT00784784
Drug: Zanamivir
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg, OD, for duration of influenza season (10-23 weeks)
Trial: NCT01182129
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine pouch, 2.2 mg, single dose, 30 minutes
Trial: NCT01182129
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewing Gum, 4 mg, single dose, 30 minutes
Trial: NCT02226510
Drug: Metformin XL
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day . They will continue on Metformin XL 500mg x2/day for 2 weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day.
Trial: NCT01096771
Drug: ClinOleic 20%
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 96 hour continuous infusion.
Trial: NCT02005601
Drug: Duloxetine 60mg
RxNorm normalized name: DULOXETINE 60MG CAP,SPRINKLE,EC
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
Trial: NCT00724035
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Procedural sedation before the execution of the block.~* 0.03 mg/kg iv bolus
Trial: NCT00724035
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.75% (wt/vol) solution, 20 ml perineural injection
Trial: NCT04183257
Drug: oral vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral Vitamin D 400IU will be given and will be escalated every 2 weeks.
Trial: NCT01096771
Drug: Intralipid 20%
RxNorm normalized name: Intralipid 20% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 96 hour continuous infusion.
Trial: NCT03151525
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IFX treatment for maintenance of remission
Trial: NCT01378754
Drug: Fospropofol (Lusedra®) 6.5
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 1 will receive 6.5 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
Trial: NCT01378754
Drug: Fospropofol (Lusedra®) 10
RxNorm normalized name: fospropofol disodium Injectable Solution [Lusedra]
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 2 will receive 10 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
Trial: NCT01378754
Drug: Fospropofol (Lusedra®) 12
RxNorm normalized name: fospropofol disodium Injectable Solution [Lusedra]
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 3 will receive 12 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
Trial: NCT03388125
Drug: N-butyl-2-cyanoacrylate
RxNorm normalized name: N-butyl-2-cyanoacrylate
DrugBank: Enbucrilate (DB12358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-butyl-2-cyanoacrylate injection group
Trial: NCT02137772
Drug: Letermovir
RxNorm normalized name: Letermovir
DrugBank: Letermovir (DB12070)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.
Trial: NCT00138125
Drug: Faslodex
RxNorm normalized name: Faslodex
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered IM at 500 mg on day 1 of cycle 1, followed by 500 mg on day 15 of cycle 1, then 500 mg on day 1 of each cycle thereafter.
Trial: NCT05468450
Drug: Ultrasound-guided-foam sclerotherapy (UGFS) using Polidocanol sclerosant
RxNorm normalized name: polidocanol Injectable Foam
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Direct injection Foam sclerotherapy
Trial: NCT03404414
Drug: 18F-FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose 18F-FDG were injected into the patients before the PET/MR or PET/CT scans.~patients before the PET/CT scans
Trial: NCT00198159
Drug: ZD1839 Iressa
RxNorm normalized name: Iressa
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00594152
Drug: CIIIT
RxNorm normalized name: Clomipramine Hydrochloride
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intravenous infusion group received three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin.
Trial: NCT01861340
Drug: Lenalidomide, Dexamethasone, and MEDI-551
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.
Trial: NCT00757523
Drug: Epiduo Gel
RxNorm normalized name: Epiduo
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
Trial: NCT00757523
Drug: Duac Gel
RxNorm normalized name: benzoyl peroxide / clindamycin phosphate Topical Gel [Duac]
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
Trial: NCT00247390
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramelteon 8 mg, tablets, orally, once daily for up to 42 weeks.
Trial: NCT03224637
Drug: Paracetamol (conventional)
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03224637
Drug: Ketorolac Tromethamine (conventional)
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03467022
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients depleted or deficient in vitamin C by blood test were supplemented orally in vitamin C 1 gram per day for three months
Trial: NCT01949662
Drug: Lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 mg by vein one time only.
Trial: NCT01949662
Drug: Haloperidol decanoate
RxNorm normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg/day by vein.
Trial: NCT01253460
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 by vein over 6 - 8 hours on day 3 of course 1 after cyclophosphamide, then at 500 mg/m2 on day 1, after cyclophosphamide for subsequent courses. Each course is 28 days.
Trial: NCT01253460
Drug: Sapacitabine
RxNorm normalized name: Sapacitabine
DrugBank: Sapacitabine (DB06365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg flat dose by mouth in the morning of days 1,2, and 3 of each 28 day course.
Trial: NCT02239094
Drug: Lurasidone (Latuda)
RxNorm normalized name: lurasidone Oral Tablet [Latuda]
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antipsychotic medication approved for use with Bipolar disorder
Trial: NCT00075751
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00075751
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00075751
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00259805
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 given as an IV infusion once weekly for four doses
Trial: NCT01819220
Drug: amlodipine/valsartan
RxNorm normalized name: AMLODIPINE/VALSARTAN
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is a phase IV clinical study. The study is a 24 week, prospective, randomized open labeled multicenter study to compare the efficacy of amlodipine/valsartan combination vs telmisartan/hydrochlorothiazide combination in reducing post prandial sugar. The study will be performed in hypertensive patients with metabolic syndrome.~Active group: Starting dose of amlodipine 5mg/ valsartan 80mg comparator group: Telmisartan 40mg/hydrochlorothiazide 12.5mg When the blood pressure is above the target goal of 140/90mmHg, up titration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed.
Trial: NCT03403101
Drug: S1
RxNorm normalized name: LS11
DrugBank: LS11 (DB05918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are planned to receive the SIRIOX regimen including S-1 (BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; oral twice daily on days 1-7, days 15-21）of every cycle.~• 28 days a cycle.
Trial: NCT03403101
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients are planned to receive the SIRIOX regimen including Oxaliplatin (OXA, 85 mg/m2; d1,d15) of every cycle.~• 28 days a cycle
Trial: NCT03403101
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients are planned to receive the SIRIOX regimen including Irinotecan (IRI, 180mg/m2; day 1,day 15) of every cycle.~• 28 days a cycle
Trial: NCT00865462
Drug: Abrika Bupropion 150 mg XL Tablet, single dose
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A: Experimental Subjects received Abrika formulated products under fed conditions
Trial: NCT00391638
Drug: TRUVADA (EMTRICITABINE + TENOFOVIR DF)
RxNorm normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Truvada ® (200 mg tablet of 300 mg of emtricitabine + tenofovir DF) Dosage 1 tablet taken orally once a day
Trial: NCT03648996
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 months of allopurinol treatment with the goal of decreasing uric acid compared to control group
Trial: NCT01930734
Drug: Dobutamine
RxNorm normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion up to 5mcg/Kg/min
Trial: NCT01856634
Drug: 100 mg Delamanid
RxNorm normalized name: delamanid
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 100 mg Delamanid BID for 10 days
Trial: NCT01856634
Drug: 50 mg Delamanid
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 50 mg Delamanid BID for 10 days
Trial: NCT01856634
Drug: 25 mg Pediatric Formulation Delamanid
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 25 mg Pediatric Formulation Delamanid BID for 10 days
Trial: NCT01856634
Drug: 10 mg Delamanid Pediatric Formulation
RxNorm normalized name: diazepam
DrugBank: Delamanid (DB11637)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients \> 10 kg will receive DPF 10 mg BID for 10 days
Trial: NCT01856634
Drug: 5 mg Delamanid Pediatric Formulation
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Patients \> 8 kg and ≤ 10 kg will receive DPF 5 mg BID for 10 days~Patients ≤ 8 kg will receive DPF 5 mg QD for 10 days
Trial: NCT03608865
Drug: Durvalumab with Tremelimumab
RxNorm normalized name: tremelimumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. All trial treatments will be administered on an outpatient basis. Durvalumab 1500mg + tremelimumab 750 mg will be administered as a 60 minute each one IV infusion every 4 weeks. Sites should make every effort to target infusion timing to be as close to 60 minutes as possible. However, given the variability of infusion pumps from site to site.
Trial: NCT00317941
Drug: Rebif
RxNorm normalized name: Rebif
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 44ug administered with Rebiject II